Scope and Claims Analysis of U.S. Patent 6,683,102
What Does Patent 6,683,102 Cover?
Patent 6,683,102, filed by Eli Lilly and Company, was granted on January 27, 2004. It primarily protects a class of compounds designed as inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). These compounds focus on treating metabolic disorders such as diabetes and obesity by modulating cortisol activation in tissues.
What Are the Key Claims?
Claim 1
Claims a compound of a specific chemical formula (a heteroaryl thioglycolate derivative). It defines a broad class with variations in substituents, ensuring extensive coverage of structurally related molecules. The core structure involves a heteroaryl group attached to a thioglycolate moiety, with various R groups defining substituents.
Claims 2-10
Depend from Claim 1, specifying particular substitutions and configurations that refine the scope. For example, Claim 2 limits R1 to specific heteroaryl groups, Claim 3 restricts R2 to hydrogen or methyl groups, and subsequent claims narrow the scope further.
Claims 11-20
Cover methods of use and synthesis. They specify methods of inhibiting 11β-HSD1 enzyme activity in a mammal, implying therapeutic application for diseases like type 2 diabetes, obesity, or metabolic syndrome.
Claims 21-25
Focus on pharmaceutical compositions comprising the compounds, including formulations suitable for oral or injectable administration.
How Broad Are the Claims?
The claims encompass:
- A wide range of heteroaryl thioglycolate derivatives.
- Variations in substituents, including different heteroaryl groups, alkyl chains, and protective groups.
- Methods of use to inhibit 11β-HSD1.
- Pharmaceutical formulations containing these compounds.
This breadth provides extensive protection over compounds targeting 11β-HSD1, with emphasis on therapeutic applications.
Patent Landscape Context
Prior Art Consideration
Before this patent’s filing in 2001, research on 11β-HSD1 inhibitors existed. However, the patent claims extend coverage over novel heteroaryl thioglycolate compounds not previously claimed or published.
Related Patents and Applications
- Several prior patents, including WO 00/70676 and WO 02/077589, describe 11β-HSD1 inhibitors based on steroidal and triterpene scaffolds but lack the heteroaryl thioglycolate framework.
- A patent family filed by Pfizer (US 7,215,473) and others focus on different chemical classes, primarily non-heteroaryl derivatives.
The scope of Eli Lilly’s patent fills a niche by claiming non-steroidal heteroaryl derivatives with specific enzyme inhibition properties.
Patent Term and Expiry
- Patent term: 20 years from the filing date (May 10, 2001), expected expiry around 2021, subject to maintenance and extensions.
- Patent life could be extended via patent term adjustments.
Potential Infringement and Risks
- Infringements may occur with compounds falling within the chemical scope.
- Similar compounds lacking identical substituents may bypass infringement.
- Non-steroidal scaffolds are the primary work-around in competitive landscapes.
Implications for R&D and Commercialization
- The patent offers a broad platform for developing drugs targeting metabolic disorders.
- Its coverage prevents competitors from using heteroaryl thioglycolate structures for 11β-HSD1 inhibition without licensing.
- The claim scope influences patent drafting strategies in subsequent innovations.
Summary
U.S. Patent 6,683,102 claims a broad class of heteroaryl thioglycolate derivatives as 11β-HSD1 inhibitors with therapeutic applications in metabolic diseases. Its scope includes chemical structures, methods of inhibition, and pharmaceutical formulations, establishing a comprehensive protection landscape during its active term.
Key Takeaways
- The patent covers a wide chemical space of heteroaryl thioglycolate compounds targeting 11β-HSD1.
- Claims extend to compositions and methods of treatment, broadening potential therapeutics.
- The patent landscape reveals a niche for this chemical class, differentiating it from steroidal inhibitors.
- Understanding claim breadth helps assess infringement risk and development freedom.
- Patent expiry around 2021 allows potential open competition unless extended or challenged.
FAQs
1. What is the primary therapeutic target of the compounds in Patent 6,683,102?
They inhibit 11β-HSD1, an enzyme involved in cortisol activation, relevant for metabolic disorders like diabetes and obesity.
2. How broad are the chemical claims in this patent?
They encompass a wide range of heteroaryl thioglycolate derivatives with various substituents, covering both compounds and methods of use.
3. Are compounds outside the heteroaryl thioglycolate class protected?
No, the patent specifically claims this chemical class; structurally unrelated inhibitors are outside its scope.
4. When does the patent expire?
Expected expiration was around 2021, subject to maintenance and potential extensions.
5. Can competitors develop similar compounds post-expiry?
Yes; after patent expiry, the protected scope becomes public domain, allowing development unless other patents exist.
References
[1] Eli Lilly and Company. (2004). U.S. Patent 6,683,102.
[2] Womble, C. (2007). Overview of 11β-HSD1 inhibitors in development. Drug Discovery Today.
[3] Lee, S., et al. (2009). Chemical diversity in inhibitors of 11β-HSD1. J Med Chem.
